Cytori is actively pursuing:
Chronic Heart Failure: Cytori has been advancing through clinical trials in the United States and Europe since 2007 with the aim of providing new treatment options to patients in need. Learn More
By Jennie Montgomery, WJBF Anchor
Augusta, GA -
UPDATED: 6pm News 3/12/14
You've heard of conventional treatments for heart patients, like stents. They're a Band-Aid compared to a cutting-edge research at the Medical College of Georgia at Georgia Regents University.
Stem cell therapy is an exciting breakthrough in regenerative medicine... using a patient's own stem cells to treat a weak heart muscle.
This is the kind of medicine that makes you think of medical technology meeting science fiction!
There is no approved stem cell therapy for the heart right now, but a national study going on at the medical college at Georgia Regents University could change all that.
WJBF News Channel 6's Jennie Montgomery has details.
This is a 3-dimensional map of the heart... and all roads lead to improved blood flow and heart function IF a clinical trial at GR Health System shows positive results.
"And the red zones are all zones that are scarred, and if you take this map and scrunch it up, like an accordion, you generate this map right here, and everything that's in red is densely scarred heart."
Dr. Adam Berman is the director of Cardiac Arrhythmia Ablation Services at GR Health System. He is the principal investigator of the study which is being done at several institutions across the country, taking stem cells from the patient's own bone marrow. The bone marrow is sent to an Aastrom Biosciences research laboratory where the stem cells are significantly expanded.
Berman then injects the stem cells back into multiple weak points in the heart-- using a catheter inserted through an artery at the groin, up into the heart.
"In the study we typically do about 20 injections within the healthier territories of the heart, with that needle, and that's the actual needle."
The difference between stem cell therapy- and conventional therapy, like a stent- is that the idea behind stem cells is "regenerative medicine," which is kind of like allowing the body to heal itself.
I stated a simple valuation reason in another post. Why don't you tell us how you value the shares?
Great Article just out read the rest onling
Organovo Holdings, Inc. 3 minutes ago
SAN DIEGO, March 12, 2014 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today celebrated a profile of the company and the 3D bioprinting space as the cover story in the Economist's Technology Quarterly.
Keith Murphy, chairman and chief executive officer of Organovo, commented that "Organovo is proud to continue to receive insightful coverage in top business and financial news outlets. We appreciate the recognition as a top tier biotechnology company showing leadership in an emerging and important space."
SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (NYSE MKT: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today issued a caution to investors regarding content on certain internet sites targeting existing and potential investors in its common stock.
Organovo and many other innovative technology companies have been the subject of various articles on certain investor websites that contain significant factual errors. The content on these sites can be submitted by independent authors and do not represent a cohesive view or the opinion of the site overall. In fact, these sites do little or no fact checking, provide little to no editorial oversight, and provide limited or no mechanisms for correction of factual errors. The company would like to help investors judge content on such sites appropriately, and point out the risks of encountering false information.
The Company would like to stress that in providing information in regards to such sites to investors, it is not claiming that all articles with a negative connotation are false. The Company respects the right of all investors and commentators to voice opinions openly. However, on some occasions information that is not factual is presented, or factual information is presented in such a way as to create a misconception. While some errors may be unintentional or simply sloppy, on some occasions it is possible that some authors may be following a "Short and Distort" strategy, where they purposefully create a negative picture after taking a short position. To be sure, not every positive article regarding the Company should be trusted either, but rather investors should bring a critical eye to all articles published on such sites, which despite having significant distribution power and readership can be lacking in content quality.
For several reasons, Organovo strongly encourages all investors to regularly review and
Sorry that should have read
Are there any attorneys on this board?
We need to stop the blatant attempt to manipulate share price based on lies by traders using published articles on public financial sites.
in a class action against the contributor of the seeking aplha article and seeking alpha as the publisher.
I really think we need to get off our collective .... and puruse this in a class action suit.
Intentional published lies in an accepted trade rag can be found for libel and damages recovered. Especially if it can be proven that the writer benefited from the lies.
their viability as a financial publisher. Seek damages.
Technology has passed the by.
Widgets they have made for years. They plod along safely doing what they do and provide a small return for producing the same toilet paper they have made for years. That is what he knows.
No, I sold at $90 and have been waiting for this opp to buy back in. Valuations are relative to super growth. Look at Amazon, FB and various others. Investors choose the valuations they can live with. Barrons is just a short trashing job.
Organovo Holdings Enters Into Agreement With Hoffmann La Roche Exploring Use Of 3D Liver Tissue in Toxicology; Terms Not Disclosed -8K
Charles Gross, Benzinga Staff Writer September 19, 2013 8:32 AM
We may be close to an update.
they are pushing trade to lower price point with low volume. Me too :)